Clinical Trials Directory

Trials / Sponsors / Molecular NeuroImaging

Molecular NeuroImaging

Academic / Other · 14 registered clinical trials.

StatusTrialPhaseStarted
CompletedAssessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects
Healthy Volunteers
Phase 12017-05-01
CompletedPhase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
Healthy Volunteers
EARLY_Phase 12017-03-03
CompletedPhase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Alzheimer Disease, Healthy Volunteers, Progressive Supranuclear Palsy
EARLY_Phase 12016-11-29
CompletedEvaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Progressive Supranuclear Palsy, Alzheimer Disease, Healthy Volunteers
EARLY_Phase 12016-08-01
CompletedEvaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET
Healthy Volunteers, Amyotrophic Lateral Sclerosis
Phase 12016-06-28
CompletedEvaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients Wit
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS)
EARLY_Phase 12015-05-01
CompletedQuantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer
Alzheimer's Disease (AD)
Phase 12015-01-01
CompletedEvaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy S
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE)
Phase 12014-02-01
CompletedEfficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to
Alzheimer's Disease
Phase 12013-04-01
TerminatedEvaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared
Alzheimer Disease
Phase 12007-10-01
CompletedEvaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
Alzheimers Disease
Phase 12007-03-01
CompletedUse of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Com
Alzheimers Disease
Phase 12007-02-01
CompletedALTROPANE® SPECT Imaging in Patients With Parkinson Disease
Parkinson Disease
Phase 22006-11-01
CompletedAn Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)
Parkinson's Disease
Phase 22004-03-01